Akumentis Healthcare awarded as “India’s Most Watched Company of the Year 2015” at Pharma Leaders Annual Meet 2015

Akumentis Healthcare awarded as “India’s Most Watched Company of the Year 2015” at Pharma Leaders Annual Meet 2015

Akumentis Healthcare recognised at Pharma Leaders Super Brand Awards 2015. The Mid Sized Pharma Major received the credible jury award in the category of India’s Most Watched Company of the Year 2015 at the historic 8th Annual Pharmaceutical Leadership Summit & Pharma Leaders Super Brand Awards 2015 in Mumbai on 30th December 2015

 


 

 

Mumbai based Akumentis Healthcare Limited which shot to limelight in demonstrating top achievement in the fiercely competitive branded formulation market in india to reach the magic figure of 100 crores during the first year of its operation received yet another feather in its cap at the prestigious 8th edition of pharmaceutical leaderhip summit & Pharma Leaders Business leadership Awards 2015 held recently in mumbai in india on 30th December 2015. Akumentis Healthcare Limited was unanimously voted by the jury members of the Network 7 Media Group as Most Watched Company of the Year 2015 for its consistent performance, medical innovations & sustained campaigns for CME’s to the medical profession.

In a letter addressed to Dr. Rajaram Samant, CEO & Chief Mentor of Akumentis Healthcare Limited, the Selection committee wrote “your performance in the indian pharmaceutical market space despite fierce competition has been remarkable resulting in making entry into top 100 companies in india. Your penetration into the domestic market & building long term relationships with the medical professionals & winning their confidence has been exemplary and no wonder and no wonder, your market dominance continues in the areas of Infertility Management, Obstetrics & Gynaecology,Osteoporosis management,Pain & Inflammation Management,Paediatrics & Geriatrics Nutrition,Gastroenterology,Ophthalmologyetc. Further, growth equity investment firm Sequoia Capital desire to invest Rs 125 crore (approximately $19 million) will result in further growth & new product launches.Akumentis  has been the unanimous choice as the India’s Most Watched Company of the year 2015 2015  at Pharma Leaders Power Brand Award 2015 at the much awaited 8th Annual Pharmaceutical Leadership Summit & Pharma Leaders Business Leadership Awards 2015 hosted by Pharma Leaders, Asia’s Most Analytical News Media in Healthcare Communications in association with the Ministry of Health & Family Affairs & Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India in the commercial capital of Mumbai on Wednesday,30th December 2015 at the Chancellor Suite of Hotel Hilton Mumbai International Airport, India. More than 300 Industry Leaders, Policy Makers, Medical Professionals, Scientists, Bureaucrats & Diplomats assembled to debate on an aptly theme Pharma Leaders 2015 – Brand India Winning. The Board Members further mentioned “You may be wondering how we chose you. The answer is that we sent out a team of Pharma Leaders analysts and industry experts on a global hunt for companies achieving dual excellence in two critical areas: Customer Value and Growth Success. Put another way, we were searching for companies that not only had a vision for a high-quality total customer experience, but used those insights to achieve growth above the industry average. We asked our global network of consultants and analysts to monitor, screen, and analyze creative practices within their regions. We spoke to industry peers. We vetted our findings with an independent board of directors. At the end of our process, one company stood out from the rest, and that company was yours”.To be a Winner in the prestigious title like  “India’s Most Watched Company of the year 2015” would never be an easy task, but it is one made even difficult due to today’s fierce competitive intensity, customer volatility & economic uncertainty – not to mention the difficulty of innovating in an environment of escalating challenges to intellectual property. In totality, you have distinctively stood apart from others, thus, your receipt of this award & recognition signifies your remarkable & outstanding achievement. Pharma Leaders Juries strongly believe that such an achievement should be acknowledged & celebrated. We are confident that your receipt of this recognition is the result of many factors ( Employees, Scientists, Customers,& investors) & years of hard work. We are always amazed by the success stories I hear about Indian pharmaceutical Companies, and Akumentis Healthcare is no exception. What began as an enterprise in  2010  with a modest beginning at its headquarter in Mumbai and has grown into one of the top pharmaceutical corporate in the country, has now  blossomed into a formidable power house in pharmaceutical business in india & aiming to be the global player by 2017 under your dynamic leadership. Your performance under tough conditions stands out to be the most watched company in 2015. This is an outstanding growth record in indian pharma space where the indian pharmaceuticals market recorded a CAGR of 12.79 per cent in 2015 from US$ 6 billion in 2005, and is expected to expand at a CAGR of 15.92 per cent to US$ 55 billion by 2020 & By 2020, india is likely to be among the top three pharmaceutical markets by incremental growth and sixth largest market globally in absolute size & the biggest advantage is that India’s cost of production is significantly lower than that of the US and almost half of that of Europe. It gives a competitive edge to India over others.Clearly & Undoubtedly, Your Firm’s accomplishments have infused the pharmaceutical industry with Innovative & path-breaking products, and your success has helped fuel our country’s economy. I appreciate the dedication & innovative spirit of your leadership, and I applaud his continued commitment to improve the healthcare standards, quality & magnitude of reach of today & tomorrow’s Healthcare”.

 


 

 

  • Akumentis was awarded as ‘Emerging Company of the Year 2012’ by Ministry of Commerce.
  • Dr Rajaram Samant, CEO and Chief Mentor, was awarded as ‘Dynamic Entrepreneur of the Year 2012’ by his Excellency K. Shankaranarayanan, Hon.Governor of Maharashtra.
  • Samant was awarded as ‘First Generation Entrepreneur of The Year’
  • Akumentis entered the Top 65 list in its first year with turnover in excess of Rs 90 crores.
  • Akumentis further sharpened its focus on its core areas and entered cosmetology in the third year.
  • Entered Top 50 ranks within three years of its launch in India
  • Akumentis voted as India’s Most Watched Pharma Company of the Year 2015 at Joint Pharma Leaders & Ministry of Health & Family Affairs, Government of India

 

Overview

Founded in 2010″Akumentis Healthcare Pvt. Ltd. is India’s most upcoming & fastest growing Pharmaceutical Company entering top 65 companies in India in the very first year of its launch. “The company is backed by a network of 7 world class manufacturing units and R & D facilities across India. The manufacturing facility is the one of the largest in Asia with WHO, GMP, ISO 9001, ISO 14001 certifications & USFDA and UKMHRA approvable. “The Company have more than 100 innovative products in the pipeline across 8-10 therapeutic segments. A healthy work environment is the pillar of existence of an organisation and a friendly culture motivates employees to associate better with a company. Akumentis believes in core values like innovation, hard work, honesty, deepest care with passion, tolerance for honest mistakes and organisation growth and development of its employees.

In Samant’s words, “Ours is an innovation driven culture, wherein we are introducing innovative products (first time in India)- this helps our field force get maximum time with doctors and is directly proportional to business and success- this is the biggest motivator to our employees. And we have special programmes to identify and help them build on their personal dreams.”

The Company is currently operating in the following segments

  • Infertility management
  • Obstetrics & Gynaecology
  • Osteoporosis management
  • Pain & Inflammation Management
  • Paediatrics & geriatrics nutrition
  • Gastroenterology
  • Ophthalmology
  • Dentist
  • Acute & Chronic infection

 

About Pharma Leaders Awards

Pharma Leaders Awards has an established record of leadership in research, innovation and in ongoing improvements to health services through strong healthcare leadership. These Awards seek to recognise outstanding health leadership by an individual or team resulting in positive change across the global health system. Pharma Leaders Awards attempt to  recognize outstanding individual and team contributions across priority areas selected by the Pharmaleaders Jury. The Pharma leaders  Award recognises outstanding leadership, by an individual or Companies for a distinctive recognition in a clear exhibition of top performances in various verticals. The Pharma Leaders Awards has also committed to being the premier award show in  healthcare that sets standards, through industry leaders as judges and navigators as well as critics who know good from great and brilliant from best. Through the Pharma Leaders Awards, we are now seeing outstanding work across the board globally, not only in the conventional media but in new media, digital, viral integrated and interactive. This is what great shows do. Celebrate, recognise and encourage us all to do better is the guiding spirit.


 

 

Koye Pharmaceuticals debuts at Pharma Leaders Power Brand Awards 2015, bags “Emerging Company of the Year 2015”

Koye Pharmaceuticals debuts at Pharma Leaders Power Brand Awards 2015, bags “Emerging Company of the Year 2015”

Koye Pharmaceuticals recognised at 8th Annual Pharma Leaders Awards for fastest growing pharma company in india in branded formulations market as the “Emerging Company of the year 2015”

Koye Pharmaceuticals, India’s fastest growing mid sized pharmaceutical company having dominant presence in the key therapeutic segments with ethical marketing network received the rare distinction at the prestigious Pharma Leaders Platform in its 2015 Annual Award Editions as “Emerging Company of the year  2015” at the 8th Annual Pharmaceutical Leadership Summit & Pharma leaders Business Leadership Awards 2015 on Wednesday, 30th December at  Hotel Hilton Mumbai International Airport, Mumbai, India where more than 300 power packed business tycoons, diplomats,healthcare leaders had assembled to be part of the historic debate on “PHARMA LEADERS 2015 –  BRAND INDIA WINNING”. The Award Trophy & Certificate of Excellence was presented in a glittering award ceremony to the founders of the company  Mr.  Preetish Toraskar and Mr. Ravindra Shenoy marked by the presence of Who’s & Who’s of the Indian Pharmaceutical Industry. Mr. Louis Banks who has often  been referred to as the Godfather of Indian Jazz & the iconic music composer was the Chief Guest of the evening conferred the awards with the presence of Mr.Satya Brahma, Chairman & Editor-In-Chief of Pharma Leaders Group, asia’s most analytical news media in healthcare communications.

Speaking at the meet Mr. Preetish Toraskar , co-founder of Koye Pharma said  on the  Healthcare Reforms in India & Koye’s commitment as “to provide fresh impetus to present healthcare reforms, I feel, as a developing country reforms would be ongoing expectations and reality. In country like ours, health-care reforms are no different. All stakeholders in the health-care space need to do their bid to ensure that collectively we create a Healthy Nation. Public Private Partnership (PPP), would thus be one of the very important model for country like India. PPAP –Public Private & Academia Partnership is what I propose as the sustainable model for a vibrant nation like ours, and we must realize its potential, and harness it to our best. Applied Research through PPAP with Strategic planning and management by government is essential.I could see PPPs and PPAP succeeding with right structure and planning in detail, and ofcourse with right-human resource in place.


Koye is an emerging healthcare company which provides a range of relevant products to aid the Indian Physicians. Today, Koye stands firm to explore and bridge the crucial gaps in current therapies. Currently, Koye focuses on optimizing, and strengthening its Women healthcare, Respiratory care, and Ortho care portfolio with novel and quality products.Embarked on a visionary journey on October 2013, Koye has become a PAN India company covering more than 100000 (0.1 million) retail pharmacies across India, with digital-driven supply chain management, and distribution capability, at par with any large cap pharmaceutical company. In a span of two years, Koye has been successful in generating more than 1000 employment opportunities in India, and made its presence felt in the Indian pharmaceutical Industry as astrong emerging company.A strong advocate of responsible corporate citizenship, Mr. Toraskar chairs many CSR Campaigns, one of such and unique one is “Care for her”. It’s an endeavour that focuses on creating awareness about breast cancer and early screening of it, through innovative devices. Regular free breast cancer screening camps are conducted simultaneously across India. More than 10,000 (ten thousand) women across India have been screened successfully, through Care for her program.Mr. Toraskar has been a popular figure among young aspiring entrepreneurs and students, for his India vision, and creating sustainable business model for a robust economy. Whenever he finds leisure, he enjoys training young entrepreneurs, and management students.

Brief Overview

Mumbai-based Koye is into essential drugs for primary specialty care with products targeting ailments such as arthritis, iron deficiency, asthma, etc. As per its website, it has over 300 sales personnel spread across the country.The firm positions its products as medicines for day-to-day well-being with brands such as Coecortt, Coekastle, Coecoral, CoeHB, etc.Koye was founded by Mr. Preetish Toraskar and Mr. Ravindra Shenoy. Toraskar has two decades of experience in the pharma sector working with firms like Cipla, Lupin, Novartis, Alkem and Mylan. In his last assignment he was head of Indian commercial operations of US drug maker Mylan.Shenoy is also a long-timer with pharma sector and in his last job was joint managing director and board member at Aurobindo Pharma Ltd. He began his career with finance department and over the years managed business operations and has also spearheaded M&As. In the past he was COO of Alkem.Sequoia, one of the more active VC firms in the country, has backed around a dozen firms in the healthcare domain including Koye. The bulk of these is in healthcare delivery or services space. Product and pharma companies that it has backed include Celon Labs and Paras Pharma, a maker of FMCG and OTC healthcare products, which was sold to Reckitt Benckiser in 2011. Sequoia Capital raised $530 million in its fourth India-focused fund last year to build on its venture and early growth investment activity in India. This new fund will invest in sectors like technology, consumer and healthcare. It was the most active VC fund in the country in 2014.


The Winning Duo

Mr. Preetish Toraskar on his current role serves as the Director and one of the founding members of Koye Pharmaceuticals Pvt. Ltd. He spearheadsCorporate&Business Strategy, and Human Resources. Under his vision and leadership, Koye has attained a substantial growth in last two years from point Zero to a 1000 (one thousand) strong team across India.

Mr. Ravindra Y. Shenoy served as Joint Managing Director at Aurobindo Pharma Ltd. from June 01, 2012 to November 9, 2012. Mr. Shenoy has more than 19 years of experience in the Pharma sector spanning both domestic and international businesses. He began his career with responsibility of finance and over the years, the span of responsibilities increased to controlling business operations as Head of Business Finance, Head of Mergers & Acquisitions and Investor Relations. Prior to joining Aurobindo Pharma, Mr. Shenoy served as the Chief Operating Officer of Alkem Laboratories Limited. Mr. Shenoy serves as a Director of Arth Welfare Foundation and Enzene Biosciences Limited. He served as Director at Aurobindo Pharma Ltd. from June 01, 2012 to November 9, 2012. Mr. Shenoy is a Graduate in Commerce followed by CWA, CS, DBF, MBA of Finance (NMIMS).


#PharmaLeadersWithSatyaBrahma
#Dec30thWithSatyaBrahma
#PharmaLeadersAwards
#PharmaceuticalLeadershipSummit2015
#Pharmaleaders2015
#BrandIndiaWinning
#8thAnnualPharmaceuticalLeadershipSummit2015
#PharmaSummit2015
#SatyaBrahma
#JournalistSatyaBrahma

Jenburkt Pharmaceuticals voted by the Network 7 Media Group as “India’s Most Promising & Valuable Company 2015”

Jenburkt Pharmaceuticals voted by the Network 7 Media Group as “India’s Most Promising & Valuable Company 2015”

Jenburkt Pharmaceuticals selected by the Jury of Pharma Leaders Board for consistent performance at Pharma Leaders Super Brand Awards 2015 Annual Ceremony

Jenburkt Pharmaceuticals, India’s fastest growing pharmaceutical company having dominant presence in the key therapeutic segments with ethical marketing network received the rare distinction at the prestigious Pharma Leaders Platform in its 2015 Annual Award Editions as “India’s Most Promising & Valuable Company 2015” at the 8th Annual Pharmaceutical Leadership Summit & Pharma leaders Business Leadership Awards 2015 on Wednesday, 30th December at  Hotel Hilton Mumbai International Airport, Mumbai, India where more than 300 power packed business tycoons, diplomats,healthcare leaders had assempled to be part of the historic debate on PHARMA LEADERS 2015 –  BRAND INDIA WINNING.

The Award Trophy & Certificate of Excellence was presented in a glittering award ceremony marked by the presence of Who’s & Who’s of the Indian Pharmaceutical Industry. Mr. Louis Banks who has often  been referred to as the Godfather of Indian Jazz & the iconic music composer was the Chief Guest of the evening conferred the awards with the presence of Mr.Satya Brahma, Chairman & Editor-In-Chief of Pharma Leaders Group, asia’s most analytical news media in healthcare communications.

In a letter addressed to Mr. Ashish Bhuta, CMD, Jenburkt Pharmaceuticals Limited, The selection committee outlined the process of selection as What began as an enterprise in  1985 with a single manufacturing facility at has grown into one of the biggest pharmaceutical corporate in the country, has now  blossomed into a formidable power house in pharmaceutical business in india & aiming at  much more bigger space under your dynamic leadership. Your performance under tough conditions stands out to be the most watched company in 2015. This is an outstanding growth record in indian pharma space where the indian pharmaceuticals market recorded a CAGR of 12.79 per cent in 2015 from US$ 6 billion in 2005, and is expected to expand at a CAGR of 15.92 per cent to US$ 55 billion by 2020 & By 2020, india is likely to be among the top three pharmaceutical markets by incremental growth and sixth largest market globally in absolute size & the biggest advantage is that India’s cost of production is significantly lower than that of the US and almost half of that of Europe. It gives a competitive edge to India over others.

 


 

Founded in 1985, Jenburkt Pharmaceuticals is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company, with its stock listed on the Bombay Stock Exchange. Jenburkt’s head quarters is located in Mumbai, from where its entire operations are handled. Jenburkt Pharmaceuticals Ltd. manufactures and markets pharmaceutical formulations in India and internationally. It offers prescription medicines in various therapeutic areas, such as anthelmintic, anti-arthritic, antibiotics, antidiabetic, anti-hypertensive, anti-inflammory analgesic, anti-malarial, anti-osteoporotic, anti-ulcerants, aphrodisiac, dermatological, gastrointenstinal, hematinics, neuropathy, and protein preparation, as well as anti-cough, cold, and allergy. The company was founded in 1985 and is based in Mumbai, India.

Strong Domestic Operations:

Jenburkt Pharma has a strong committed team of more than 575 sales force across India, Jenburkt promotes all its 85 brands ethically across 75,000 doctors and 50,000 chemists regularly. Backing the strong force company has more than 1000 stockists and 25 superstockists. Jenburkt also caters to large Government, Semi-Government Institutions, Missionary Hospitals, Public Sector Enterprises, etc.

Growing International Exports:

Currently, Jenburkt’s products are being exported to 15 countries globally with a clear focus to expand on a yearly basis. Also Jenburkt is open to partnering foreign pharmaceutical firms to market their pharmaceutical products in India; Company is also in search of a capable partner to market their pharmaceutical products across the globe through which they can improve on their exports sales which constitutes small proportion of total sales.

jenburkt

Strengthening the Brand:

Company is focused on strengthening their brands in their respective segments during the last year. There is a growing trend of competition from regional companies who operate either in a few districts or in a few states in India. This is apart from the competition from large organizations operating in India. Neuropathy detection camps and bone densitometry camps were carried out in various parts of the country for detection of neuropathy and osteoporosis.. The strategy of Company is to focus on long term therapies in acute and chronic ailments, by moving up the value chain continuously. As a result, a few of the Company’s brands are the preferred choice in certain segments. Company has some strong brand like CARTI SAFE FORTE (Anti Arithritic) , POWERGESIC Tablets (Anti Inflammory Analogesic).They rank among the top five in those segments.

Quality Portfolio of Products:

Jenburkt has good health through quality products that include prescription and over-the-counter drugs. Their prescription medicines span across various therapeutic areas such as anti-arthritic, antimalarials, anti-osteoporotic, antibiotics, antidiabetics and anti-inflammatory drugs and more. Hence Company has good quality of products in their portfolio.

Strong Manufacturing Facilities:

Company has the state-of-the-art manufacturing plant at Sihor-Gujarat, in India. The plant is modern and well-equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical and healthcare products. Company’s plant is approved as per W.H.O Guidelines with current G.M.P requirements, apart from approvals from various countries. Furthering the development of formulations, Jenburkt has a Research & Development unit duly approved by the Ministry of Science & Technology, Government of India. Hence company has strong manufacturing facilities to cater both domestic and international market. Also Jenburkt has a progressive lineage of manufacturing high quality formulations backed by a strong Research & Development, Regulatory and global marketing team. The big thrust of Jenburkt’s strategy is to focus on creating a new category in the Indian and the International pharmaceutical market vis a vis.

Recent R&D Activities:

Recently company undertook commercial scale manufacturing of Frendacid, an antacid and antiflatulance for export market. Also Company continue to work towards formulating new and existing molecules for domestic and international market for efficient and cost saving drug delivery systems. Hence company is in continuous process of improving on its product portfolio.

Top Cardiologist Dr. Kaushal Pandey honored at Pharma Leaders Super Brand Awards 2015

Top Cardiologist Dr. Kaushal Pandey honored at Pharma Leaders Super Brand Awards 2015

Asia’s Most Valuable & Breakthrough Innovator in Cardio Thoracic  & Vascular Surgery 2015 Award Conferred to Dr. Kaushal Pandey, Cardio Thoracic and Vascular Surgeon

The 8th Annual Pharmaceutical Leadership Summit & Business Leadership Awards was successfully concluded at the financial capital of india in Mumbai at Hotel Hilton today where more than 300 top leaders of the healthcare industry had gathered to be the part of the historic debate on  “Pharma Leaders 2015, Brand India Winning”. Widely acclaimed in the healthcare industry as the pioneer in recognizing the leaders of today & tomorrow, Pharma Leaders brought together veteran healthcare leaders under one platform. The leadership Summit in the afternoon session debated crucial topics such as Healthcare Insurance, Medical Tourism, Challenges of Indian Pharma Industry. Hinduja Hospital CEO Mr. Gautam Khanna debated on the challenges of Indian Healthcare Insurance while Padma Sree Prof Dr. Shashank Joshi addressed on Brand India.

 

 

 

Dr.Kaushal Pandey made a passionate presentation on World Class Individuals : mediocre institutions: & failing medical education. The Award Winning Cardiac Surgeon stressed the need for qualatative improvement of healthcare services in the country to make healthcare accessable to the indian masses.

Expressing concern over the falling standard of education in both public and private medical colleges affecting patient care and healthcare quality in the country, Dr Kaushal Pandey, one of the renowned consultant cardiovascular surgeons associated with P. D. Hinduja National Hospital & Research Center, has stressed on the need for a major overhaul of the medical education system to produce quality doctors to ensure high quality healthcare.

“India produces around 50,000 MBBS doctors annually as compared to 18,000 doctors in USA but training of our doctors are not up to the mark as compared to doctors abroad. In India, the MBBS students do not get enough exposure to clinical materials and surgical procedures during the course to become well trained doctors, and there are a chunk of students who don’t have aptitude to become a doctor but they join a medical college just because their parents manage to secure seats for them in the medical college. Such doctors are risk for patients. The quality of the faculty in medical colleges is also not up to the mark,” said Dr. Pandey.

There is no legal compulsion for doctors to undergo re-training in the country. There is no system to audit the doctors on any quality of care measures which provide them freedom to do whatever they want after the basic qualification is secured. In absence of scrutinisation and monitoring to ensure accountability of doctors in public hospitals in both urban and rural areas, absenteeism among doctors has become common sight leaving scores of needy patients in lurch. It is not the case with private hospitals which have a stringent monitoring system to make doctors accountable to patient care, he said.

“If the government is really worried about people’s health and if the country is to stay competitive globally, it has to exercise its authority to introduce reform to medical entrance test so that students having aptitude to become a doctor get admission to medical colleges. Commercialisation of medical education flooding the market with poor quality doctors should be stopped at the earliest without any loss. The exorbitant capitation fees charged by private medical institutes from students should be regulated to make education affordable for deserving and needy students and steps need to be taken to overhaul the regulatory framework pertaining to quality of instruction, faculty development and curbing private practice,” noted cardiac surgeon said.

In order to overcome the shortage of quality faculty members in public medical colleges, the government needs to revive the old honourary system attached to healthcare in the country where talented, renowned doctors used to conduct classes for students in government medical colleges for two-three days imparting them theoretical and practical insight into the course. They used to charge nominal fees for it, he added.

He said that the government also needs to make integrated protocol-based diagnoses and treatment systems into the teaching programme for medical students and make them take a test after a certain period to ensure their skills updation and encourage use of technology with applications like clinical decision support systems to improve the quality of healthcare delivery.

Geographical location and infrastructure facilities should be taken into account in starting an AIIMS like institutes in the country by the government to ensure maximum optimisation of such facilities, he concluded.

Of the 4,000-odd multi-crore infrastructure projects in the country, only nine (0.21%) – with a total investment of Rs 938 crore – are in the health sector, according to data published by the finance ministry.The public-private partnership (PPP) projects range from diagnostic centres to super-specialty hospitals. Investments in the health sector are far lower than those in the transport and energy sectors. The lack of health facilities in India’s villages reflects the low investment.About 20% (35,389) of the 182,709 public health facilities in rural areas do not have their own premises, according to a 2014 rural health statistics report. There was a shortage of 6,700 (23%) public health centres and 2,350 (33%) community health centres as of March 31, 2014, according to data tabled in the Rajya Sabha.Government spending on health has come down from Rs 37,000 crore ($5.5 billion) in 2013-14 to Rs 30,000 crore ($4.5 billion) in 2014-15. India spent $69 per capita on health in 2013, the lowest among developing nations. Even poorer economies like Indonesia and Mexico did better, according to data published by the Organization for Economic Co-operation and Development


Dr.Kaushal Pandey received the prestigious award title “Asia’s Most Valuable & Breakthrough Innovator in Cardio Thoracic  & Vascular Surgery 2015from the hands of the iconic music composer Louis Banks who has often  been referred to as the Godfather of Indian Jazz  in the presence of Satya Brahma, Chairman & Editor-In-Chief of Pharma Leaders Group.

Dr.Kaushal Pandey is one of country’s top cardiologist & is much respected & admired in the healthcare profession.Dr.Kaushal Pandey specializes in Cardiovascular & Thoracic Surgery & his area of Interest are in Bilateral IMA and Radial Artery Grafts for CABG, LV Aneurysm and CABG in poor L V function,Bio Prosthetic Valve Replacement,Redo Valve and Redo CABG Surgery,Infective Endocarditis and infections in Cardiac Surgery & his Key Achievements include among many are winning  P. K. Sen Memorial Oration award at Indian Association of Cardiovascular thoracic Surgeons Conference, 2006, Dr. K. N. Dastur Memorial Oration award at IACTS CON 2012. Dr.Kaushal Pandey is credited with performing of over 14500 open-heart surgery procedures in Mumbai since 1991,Over 50 major presentations and articles in national and international conferences and journals.In the year. Pharma Leaders crowned him as Incredible Medical Expert of the Decade in the year 2013 & Indian Affairs ( A Division of Network 7 Media Group) felicitated the accomplished cardiac surgeon as India’s Most Promising Face in Cardiology at the 3rd Annual India Leadership Conclave & Indian Affairs Business Leadership Awards 2015.


Microlab’s CARIPILL receives Emerging Brand of the Year at the 8th Annual Pharmaceutical Leadership Summit & Pharma leaders Business Leadership Awards 2015

Microlab’s CARIPILL receives Emerging Brand of the Year at the 8th Annual Pharmaceutical Leadership Summit & Pharma leaders Business Leadership Awards 2015

The 8th Annual Pharmaceutical Leadership Summit & Business Leadership Awards was successfully concluded at the financial capital of india in Mumbai at Hotel Hilton today where more than 300 top leaders of the healthcare industry had gathered to be the part of the historic debate on  “Pharma Leaders 2015, Brand India Winning”. Widely acclaimed in the healthcare industry as the pioneer in recognising the leaders of today & tomorrow, Pharma Leaders brought together veteran healthcare leaders under one plattform. The leadership Summit in the afternoon session debated crucial topics such as Healthcare Insurance, Medical Tourism, Challenges of Indian Pharma Industry. Microlab’s CARIPILL received the top recognition at the Pharma Leaders Power Brand Awards. Mr. Ashok Jain, Executive Director of Microlabs received the Trophy & Certificate of Excellence from Mr. Louis Banks who has often  been referred to as the Godfather of Indian Jazz & the iconic music composer was the Chief Guest of the evening conferred to top achievers of the country & urged the industry to provide affordable medicines to the common masses in india.

 Satya Brahma, founder of Pharmaleaders in the opening address lambasted the union government for the faulty healthcare reforms & policy paralysis. In a scathing attack to the policy makers, Satya said “the Healthcare Challenges in India at present are of different dimensions & more of cleaning the system at the helm who are responsible for formulating laws, rules & regulations. While we can’t ignore the concerns of the pharma companies facing complex issues in regulatory legal hurdles in IPR challenges, pricing &other issues related to patent regime. Pharmaleaders believe that the evolving global and domestic market dynamics are likely to result in significant opportunities and challenges for pharma companies operating in India, both Indian companies as well as Indian affiliates of MNC companies. Some key issue areas are already starting to capture the attention of leadership teams within the industry.


Bengaluru-based Micro Labs, a fully integrated pharma company recently launched Caripill, which helps to increase the platelet count in patients suffering from dengue.  Approved by the scientific and regulatory authority, the pill is made from Carica Papaya leaf extract and reportedly does not have any side-effects.  Being a product of extensive R&D and clinical trials conducted by Micro Labs, the pill has proved its safety and efficacy in about one lakh patients across India, claims a company release.

MicrolabsCaripill Syrup Pack shotCaripill Tablet Pack shot
Speaking about Caripill, Dr AC Gowda Fortis Hospital, Bangalore and Principal Investigator, Clinical Trial for Caripill said, “The encouraging results on the dengue patients has shown the immense potential of what Caripill is capable of, that eventually can be administered on patients with other life-threatening diseases, like leukaemia among others, which requires intense chemotherapy leading to loss of platelets.” He added, “After an extensive research across two years conducting clinical trials on 250 patients, we have seen positive results with a dramatic decrease in the haemorrhage condition, besides, none of the patients who are administered the drug have had to undergo blood transfusion so far.”

Caripill costs Rs 25 per tablet with the dosage of administering one pill (1100 mg) three times a day, for five days.

No specific treatment was available for treating dengue, except for some paracetamol tablets (mostly Dolo 650 by Micro Labs) to reduce the fever/ temperature. However, immediately post the fever reduces, the platelets count on blood starts falling leading to serious health consequences. Despite considerable efforts to control the mosquito population, dengue fever has emerged, spread and established itself rapidly. Looking into the limited current modalities of treatment and its affordability to a fewer sections of population, Caripill can be of considerable use.

Ashok Jain, Executive Director, Micro Labs, stated, “Over four decades, we have been successful in manufacturing oral solids, liquids, topical and injectable medication for patients across verticals – diabetology, cardiology, ophthalmology, dermatology, pain/analgesics, etc.  Today, I would like to congratulate our team at Micro Labs for making a remarkable breakthrough in treating moderate to severe dengue cases with the newly introduced Caripill that comes at an affordable cost.”

Dr Nagabhushan KH, VP-Medical Services, Micro Labs, stated, “At present, the popular treatment for dengue is by oral consumption of juice crudely extracted from the non-standardised and unhygienic papaya leaves with no clear dosage specified, that could have a detrimental impact on sufferers. Our new Caripill, has received positive feedback from doctors treating patients with dengue and are confident the usage of the pill can be further extended to treating patients with other life-threatening disorders that require restoration of blood platelets.”  He further added, “The rising number of dengue cases among children, has driven us to introduce a paediatric Caripill syrup for easy consumption and plan to launch it soon.”

Caripill has been made available in all major pharmacies across India.

Reportedly it doesn’t have any side effects. According to the clinical trials, Caripill has shown positive results. A plus point is, none of them had to undergo blood transfusion. And henceforth, they are thinking of utilizing in patients with leukemia who have thrombocytopenia post chemotherapy, in future. As far as I have come across, it costs 25/- per tablet. Presently if we see the limited modalities of treatment, and the fact that it can be afforded only by fewer strata of the society, I think yes, Caripill can be worth it. Yes, caripill has some questions before it is fully accepted as platelet booster. However, given the scenario of dengue where platelet transfusion is the only option for severe depletion, caripill is a worth trying drug. Totally chemical free, I do recommend its usage and have found it to be useful. It defenitely reduced the need for platelet transfusions in some but not in all., to me, it is a worth trying drug but make sure you take it only after your doctor suggests it.Yes Micro Labs has introduced Caripill which is tablet containing leaf extract of papaya (Carica Papaya Leaf extract). It is available in market and many doctors are prescribing & have found it to be useful. However, it is advised to be taken after discussing with your doctor. One should know when to start taking Caripill (ie at what level of platelet count) and doctors are best to judge. You can contact Micro Labs @ +919845855122 by sending a message with your details and a request to call back. Caripill Cell will call back with more information.


Established in 1973, Micro Labs Limited is a multi-faceted healthcare organization with a proficient marketing team, state-of-the-art manufacturing facilities and R&D centres that are at par with international standards. All this, robustly backed by a strong distribution network and path-breaking research work has placed us amongst India’s fast growing transnational healthcare organizations.
In  Indian Pharmaceutical Market, Micro labs is ranked 15th among prescriptions (as per SMSRC Jul’15) and 19th in sales (as per AWACS MAT Sep’ 15).The brand portfolio of Micro Labs includes some of the topmost brands in various specialties like Cardiology, Diabetology, Anti-infectives, Ophthalmology, Pain, etc. Amidst our proud achievers is Dolo, an award-winning brand highly prescribed for fever management.Micro Labs is poised to achieve unparalleled status in the global pharmaceutical industry. Backed by a profound and resolute vision, we now have our eyes set on attaining the $1 billion mark by 2017.

Other accomplishments include:

  • Brand Dolo won ‘Best Managed Brand Award’ awarded by the Institute of Pharmaceutical Healthcare Management & Research’s conference in 2010
  • Dolo 650 was awarded as ‘Brand of the Year 2013’ at 6th Annual Pharmaceutical Leadership Summit 2013
  • Dolo 650 also won the Brand of the Year 2014 GOLD award and Amlong won Brand of the Year 2014 BRONZE Award at AWACS Marketing Excellence Awards 2014
  • Dilip Surana has been been honoured time and again with prestigious awards such as the ‘Dynamic Entrepreneur of the year 2010’, honoured as the Great Son of Karnataka’ by Governor of Karnataka his Excellency HR Bhardwaj in 2011
  • Dilip Surana has been bestowed with the title of ‘Most Dynamic Entrepreneur of the Year’ at 4th Annual India Leadership Conclave and Indian Affairs Business Leadership Awards 2013. He was also honoured as‘Entrepreneur of the Year 2014’ in the following year.
  • Micro Labs has also introduced a lot many number of formulations for the 1st time in the country like Anxit, Dolo-650,Silybon,Ebast and Caripill
  • Various manufacturing facilities of Micro Labs have bagged Quality Excellence awards consistently year after year

Milestones:

  • 19 specialty divisions,with a wide product range and a dedicated field force of 4500 plus.
  • 14 World class manufacturing facilities approved by various agencies including US FDA, UK-MHRA, MCC-South Africa, Health Canada, WHO, TGA Australia & Medsafe-New Zealand, with 2000 qualified technical personnel
  • A vibrant presence in over 40 countries, exporting formulations in all major therapeutic segments
  • Three R&D centres with more than 250 experienced scientists
  • GDA foundation runs the Surana College and Surana PG centre in Bangalore and “Smt. Pyaribai Chunnilalji Surana Charitable trust runs Shree Parshwa Susheel Dham”, a magnificent Jain temple in Attibele, Bangalore

The company is also at the forefront in social contribution, striving to be a model corporate citizen in terms of Social Initiatives with significant contributions in the areas of education and health.

Pharma Leaders Super Brand Award & Recognition to Top Hair Transplant & Cosmetic Plastic Surgeon Dr. Viral Desai

Pharma Leaders Super Brand Award & Recognition to Top Hair Transplant & Cosmetic Plastic Surgeon Dr. Viral Desai

 Eminent Hair Transplant & Cosmetic Plastic Surgeon voted by Network 7 Media Group Jury as “India’s Most Promising Hair Transplant Surgeon 2015” & “India’s most Admired Plastic & Cosmetic Surgeon 2015”

Noted Hair Transplant Surgeon who has been in news for bringing revolutionary treatment process in Hair Transplant & Cosmetic Plastic Surgery received the prestigious & coveted Award & Certificate of Excellence in two important categories such as “India’s Most Promising Hair Transplant Surgeon 2015” & “India’s most Admired Plastic & Cosmetic Surgeon 2015” from the hands of India’s top Music Composer & a living legend Louiz Banks with the presence of Satya Brahma, Chairman & Editor-In-Chief of Pharma Leaders, a leading media title in healthcare journalism.  Speaking to the media on receiving the recognition at the top healthcare platform, Dr. Viral Desai Aesthetic & Cosmetic Plastic, Laser, Reconstructive Surgeon & Medical Director at  DHI India, Medical Director – CPLSS said “It indeed is a great privilege and honor to be receiving the award where the top healthcare leaders of the country are present & this award reflects our efforts in the field of Hair Transplant Surgery & Cosmetic Plastic Surgery. Dr Viral Desai received the award at the platform where more than 300 healthcare leaders of the country were present in Mumbai on 30th December 2015. The ace Hair Transplant surgeon also presented a talk on “Patients First in Healthcare : the challenge of creating a new and improved Medicare”. The panel discussion on Will Innovations in India drive the next generation of global cosmetics Dermatology trends ? was acrtively participated by Dr Desai with top skincare leaders of the country such as Dr Manoj Khanna,Plastic Surgeon, Dr. Sumita Shankar, Plastic, Cosmetic & Wound Surgeon, Dr Nilyini G, Cosmetic Dermatologist, Founder, Blu Skin Cosmetology, Dr. Rashmi Shetty,Non-Surgical Aesthetic Medicine Expert , Dr. Poorva Shah,Cosmetic Dermatologist, Ms. Kiren Shrivastav, CEO & Founder, Molecule Communications.


About Dr. Viral Desai

Aesthetic & Cosmetic Plastic, Laser, Reconstructive Surgeon
Medical Director – DHI India, Medical Director – CPLSS

He always saw himself becoming a best surgeon. Even as a child growing up in Mumbai, India, Dr. Viral Desai always dreamt of becoming a doctor. He grew up in a family of doctors – all specialists in their respective fields. His father, Dr. Ramesh Desai, was a Radiologist and Sonologist; Dr. Sarla Desai, his mother, is a Gynaecologist and Obstetrician.

Dr. Desai charted his dream and graduated from medical school (MBBS) from L.T.M.M. College, Sion. He then joined residency in General Surgery and Oncosurgery at Tata Hospital, KEM Hospital and Cooper Hospital. Soon thereafter, he took up the Super-Speciality in Plastic Surgery (M.S.) course at Sir J. J. Group of Hospitals, Mumbai, for the sheer gratification of beautifying lives through aesthetic surgery and “promptly visible results” offered by plastic surgery.

With a desire to be on par with the world’s best, Dr. Desai completed a fellowship in Advanced Cosmetic and Aesthetic Surgery and Laser Training at Singapore with Dr. Woffles Wu – a teaching faculty with the International Aesthetic Surgery Society and the inventor of the Stealth Incision for breast implant. Dr. Wu is renowned for refining various surgical procedures such as liposuction, chin implants, nose jobs, lip sculpting and eyelid surgeries and has invented over ten cosmetic surgery procedures. Dr. Desai took up a fellowship in the Cosmetic Surgery Department at Singapore General Hospital, where he worked with nine cosmetic surgeons and gained from their vast experience.
While working with Dr. Wu, Dr. Desai has fine-tuned the art of various surgical procedures such as Liposculpting, Breast Implants, Eyelid Surgeries, Nose Jobs, Chin Implants, etc. Dr. Viral Desai is today an advanced BOTOX and Fillers user and trainer in India, and has the distinction of performing the maximum number of Botox and Fillers procedures over the latest few years. He also is the pioneer of Non-Surgical Facelift (WAPTOS), Threadlift (APTOS) in India. Dr. Desai has conducted various training workshops in Advanced Botox and Fillers for doctors and has been a faculty for lectures at various medical and non-medical fraternity gatherings.

Dr. Desai is known for communicating with his patients to understand their real needs. “I talk to them at length to get a grasp of what they want”. He likes to screen his patients for “realistic expectations”, and is being prompt to tell patients if their expectations are unrealistic. He believes in giving his patients accurate and complete information of the procedures. Dr. Desai developed his sense of aesthetic surgery as a natural extension of his interest in art and drawing – having done Elementary and Intermediate courses in Art. Most important in a plastic surgeon, he feels, are “common sense and a good artistic inclination”.Dr. Desai is the Medical Director of CPLSS Mumbai and the founder, promoter and Medical Director of DHI in India. All DHI doctors in India are trained and certified by Dr. Desai. He is also the Director of Sarla Hospital and ICU and of Desai Hospitals Pvt. Ltd. In recognition of his achievements in the field of plastic and cosmetic surgery, Dr. Desai was awarded the Icon of Plastic and Cosmetic Surgery in India Award in 2010 at the national level.

Dr. Desai is a board-certified surgeon, M.Ch. (Masters Super-speciality Degree) and D.N.B. (Diplomate of National Board) in Cosmetic and Plastic Surgery. These are the highest level of education degrees in the medical field. The D.N.B. qualification is recognized across all Commonwealth nations.

Dr. Desai is member of International Society of Aesthetic Plastic Surgery (ISAPS), Association of Plastic Surgeons of India (APSI), Indian Association of Aesthetic Plastic Surgeons (IAAPS), CSI, Maharashtra Association of Plastic Surgeons, Consultants Association of India, Indian Medical Association (IMA), Santacruz Medical Association, General Practitioners Association and other associations.

About Pharma Leaders Super Brand Awards


Pharmaleaders Power Brand Awards are the most prestigious annual industry awards, recognized annually that acknowledge and honor individuals and organizations for their remarkable accomplishments. These set of awards are widely acclaimed in the industry circle as   fitting tribute to those individuals and companies that have gone the extra mile to advance the excellence in healthcare through best practices, initiatives,dynamism,drive & towering  leadership. Pharmaleaders Business Leadership Awards are the premier largest business and technology leadership awards program in the sub continent , covering the set of prestigious awards spanning from biotech to Healthcare to CEO awards. Pharma Leaders Power Brand Awards are conferred to those Companies & Individuals who exhibit rare display of innovation for Outstanding Academic & Professional Leadership to individuals & Companies. This top recognition symbolizes the best out of best from chosen few.

Over the last one decade, since the institutionalization of recognizing excellence in healthcare & pharmaceutical business in the form of Pharmaleaders Business Leadership Awards , Pharmaleaders,  has recognized successful individuals and organizations that have empowered the healthcare industry in the global map by creating values & manufacturing prowess. These Pharmaleaders and organizations inspire the public by motivating others to carry out their calls to action, by serving as a champion for their cause and by demonstrating a clear record of accomplishment in addressing urgent, relevant and complex healthcare needs , problems & solutions. They also maintain consistent, long-lasting relationships with the people and communities in which they work. They are truly trendsetters. Thus the Annual Pharmaceutical Leadership Summit &Pharmaleaders Business Leadership Awards conducted years after years, are truly India’s only dedicated celebration of excellence in healthcare innovation, pharmaceutical & medical excellence and brand transformation. Most eagerly awaited annual affair in india, these set of awards reflect benchmark of credibility, leadership spirit & regarded by the industry experts as “Pharmaleaders Power Brands & now Super Brands.

 

 

 

 

 

Iconic Music Composer Louiz Banks awards Molecule Communications Most Promising & Valuable Communication Agency 2015

Iconic Music Composer Louiz Banks awards Molecule Communications Most Promising & Valuable Communication Agency 2015

Molecule Communications recognised at Pharma Leaders Power Brand Awards 2015 for redefining the communication & Media segments for path-breaking initiatives & innovative campaigns. 

Molecule Communications, a 360 degree media solutions and content company, one of the few which is adept in strategic media relations for brand building with operations pan India and New York providing services and solutions on all platforms of media, from print to electronic received a rare recognition at the asia’s biggest healthcare leadership meet at the  8th Annual Pharmaceutical Leadership Summit & Pharma leaders Business Leadership Awards 2015. Ms. Kiren Shrivastav, CEO & Founder of Molecule Communications received the prestigious & coveted Award & Certificate of Excellence from the hands of India’s top Music Composer & a living legend Louiz Banks with the presence of Satya Brahma, Chairman & Editor-In-Chief of Pharma Leaders, a leading media title in healthcare journalism.

Speaking to the media on receiving the recognition at the top healthcare platform, Kiren Shrivastav, CEO & Founder of Molecule Communications said “It indeed is a great privilege and honor to be receiving the award where the top healthcare leaders of the country are present & this award reflects our efforts to initiate innovative & creative communication plans & campaigns that we have served to our clients. We at Molecule want to bridge the gap between global entertainment industries, create an essential space for different worlds to meet and collaborate; encourage interactions between industries and the public forum. We foster valuable relationships between people from various sectors of entertainment industry including filmmaking and music. By producing panels and workshops featuring a diversity of highly-respected, successful professionals, Molecule Communications has quickly become an invaluable source for insights into emerging global markets for filmmaking and music.We have clients from various sectors like sports, corporate, entertainment, TV, cinema, music and fashion”.

Pharmaleaders Power Brand Awards are the most prestigious annual industry awards, recognized annually that acknowledge and honor individuals and organizations for their remarkable accomplishments. These set of awards are widely acclaimed in the industry circle as   fitting tribute to those individuals and companies that have gone the extra mile to advance the excellence in healthcare through best practices, initiatives,dynamism,drive & towering  leadership. Pharmaleaders Business Leadership Awards are the premier largest business and technology leadership awards program in the sub continent , covering the set of prestigious awards spanning from biotech to Healthcare to CEO awards. Pharma Leaders Power Brand Awards are conferred to those Companies & Individuals who exhibit rare display of innovation for Outstanding Academic & Professional Leadership to individuals & Companies. This top recognition symbolizes the best out of best from chosen few.

Kiren Shrivastav, the brain behind the communication machine of the award winning Agency, Molecule Communications,  is the key business strategist and a versatile media expert. After garnering enough experience and knowledge in event, films and media management, Kiren displayed rare business acumen by setting up this boutique media services company in 2007. She is best at people management which allows her impeccable project supervision and execution. She spearheads the functioning and growth of Molecule group. Being young and open to new radical ideas, Kiren takes an open minded approach to work along with calculated risks. She has a passion for music and dancing that makes her cheerful that she is. Her clarity of thought combined with a very base level understanding of the lowest common denominator allows her to understand the needs of the clients and the employees. Like a magician she turns ideas into reality. Her dream is to make this company known not just for its work but for its approach and professionalism. She aims at getting the IPO of Molecule Group which has marketing communications, media relations, motion pictures and television.

Pharma Leaders Super Brand Awards Conferred to Nation’s Top Healthcare Leaders

Pharma Leaders Super Brand Awards Conferred to Nation’s Top Healthcare Leaders. Huzaifa Khorakiwala of Wockhardt, Varun Khanna of BD India, Emcure Pharma, Akumentis Healthcare,Koye Pharma, Bajaj Allianz,Abbott India among others shined at Pharma Leaders 8th Annual  Awards 2015

The 8th Annual Pharmaceutical Leadership Summit & Business Leadership Awards was successfully concluded at the financial capital of india in Mumbai at Hotel Hilton today where more than 300 top leaders of the healthcare industry had gathered to be the part of the historic debate on  “Pharma Leaders 2015, Brand India Winning”. Widely acclaimed in the healthcare industry as the pioneer in recognising the leaders of today & tomorrow, Pharma Leaders brought together veteran healthcare leaders under one plattform. The leadership Summit in the afternoon session debated crucial topics such as Healthcare Insurance, Medical Tourism, Challenges of Indian Pharma Industry. Hinduja Hospital CEO Mr. Gautam Khanna debated on the challenges of Indian Healthcare Insurance while Padma Sree Prof Dr. Shashank Joshi addressed on Brand India. 

Satya Brahma, founder of Pharmaleaders in the opening address lambasted the union government for the faulty healthcare reforms & policy paralysis. In a scathing attack to the policy makers, Satya said “the Healthcare Challenges in India at present are of different dimensions & more of cleaning the system at the helm who are responsible for formulating laws, rules & regulations. While we can’t ignore the concerns of the pharma companies facing complex issues in regulatory legal hurdles in IPR challenges, pricing &other issues related to patent regime. Pharmaleaders believe that the evolving global and domestic market dynamics are likely to result in significant opportunities and challenges for pharma companies operating in India, both Indian companies as well as Indian affiliates of MNC companies. Some key issue areas are already starting to capture the attention of leadership teams within the industry.

The highlight of the seminar was the panel discussion on “Will Innovations in India drive the next generation of global cosmetics Dermatology trends ?” where country’s top doctors & industry debated on the latest innovations in the cosmetic Dermatology field. The panellists argued that the skin care category is going to be the  the next  big business area of the sector the world over & hence the industry will have a unique opportunity to see the latest technologies in this segment, presented by companies from different countries at the forthcoming in-cosmetics also the treatment process of the Cosmetic Dermatologists. India is considered by many as a hotbed of innovation. However, innovating successfully in India is far from easy. But, as we debate Breakthrough Innovation & Path-Breaking Treatment Process, success is rooted in three core principles of Demand-driven Innovation: demand-driven insight, demand-driven development, and pervasive leadership. Noted Plastic and Cosmetic Surgeon Dr. Viral Desai, Dr Manoj Khanna,Dr. Rashmi Shetty, Dr Nilyini G, Ms. Kiren Shrivastav, of Molecule Communications were among those part of the brainstorming session.

Addressing the industry leaders & leading faces of the medical profession, Mr. Louis Banks who has often  been referred to as the Godfather of Indian Jazz & the iconic music composer was the Chief Guest of the evening conferred to top achievers of the country & urged the industry to provide affordable medicines to the common masses in india.

The Evening Award ceremony was marked by the presence of the top business leaders, Industry stalwarts, politicians, eminent healthcare leaders, medical professionals.

The award Winners are :

Social Entrepreneur of the Year 2015

Dr. Huzaifa Khorakiwala, CEO, Wockhardt Foundation

India’s Most Promising & Valuable Company 2015

Jenburkt Pharmaceuticals Limited

Change-Agent in Healthcare Innovations 2015

Adroit Biomed Ltd

Pharmaleader of the Year 2015

Mr. Prakash Kumar Guha, Managing Director, Zuventus Healthcare  Limited

India’s Most Admired Health Insurance Company of the Year 2015

Bajaj Allianz Health Insurance Company Ltd

CEO of the Year 2015

Mr. Tapan Singhel, CEO & MD, Bajaj Allianz General Insurance Company Ltd

Mr. Varun Khanna, Managing Director, Becton Dickinson India  Private Limited 

Innovative Breakthrough in Cancer Research & Patients Safety 2015

Emcure Pharmaceuticals Ltd

Emerging Company of the Year 2015

Koye Pharmaceuticals Pvt  ltd

India’s Most Watched Company of the year 2015

Akumentis Healthcare Ltd

Most Promising Expert in Regenerative Medicine 2015

Dr. Deepak Chaturvedi, Physician Endocrinologist, Diabetologist

Innovative Breakthrough in Side-Effect-Free Healthcare Solution  Provider 2015

Advanced Vital Enzymes Ltd

India’s Most Promising Hair Transplant Surgeon 2015

Dr. Viral Desai, Medical Director & Founder, DHI Hair Transplant

India’s most Admired Plastic & Cosmetic Surgeon 2015

Dr. Viral Desai, Plastic & Cosmetic Surgeon

Asia’s Most Valuable & Breakthrough Innovator in Cardio Thoracic  & Vascular Surgery 2015

Dr. Kaushal Pandey, Cardio Thoracic and Vascular Surgeon

Most Valuable & Admired Hospital 2015

Hinduja Hospital and Medical Research Centre

India’s Most Admired Medical Technology Company of the year

Becton Dickinson India Private Limited

Change-Agent in Women’s Healthcare

The Good World Foundation

India’s Most Inspiring Women Business Leader in Cosmetic  Dermatology 2015

Dr. Chytra. V. Anand, Founder & Chief Medical Director Kosmoderma

Innovative Cosmetic Dermatologist 2015

Dr . Nilayini G, Founder, Blu Skin & Cosmetology Clinic

Most Promising & Valuable Communication Agency 2015

Molecule Communications Pvt. Ltd

Physician’s First Choice as Most Valuable & Admired Pharma  Company 2015

Abbott India Limited

Most Promising Sexual Health Physician and Counselor 2015

Prof. Dr Deepak K Jumani

Emerging Brand of the Year 2015

CARIPILL

Lifetime Achievement Award

Prof R. D. Joshi

Breakthrough Innovation in Facial Plastic Surgery

Dr. Debraj Shome

Most Valuable & Admired Cosmetic Dermatologist 2015

Dr.Rinky Kapoor

India’s Most Promising & Valuable Nutrition & Wellness  Centre in Diet & Nutritional Counseling 2015

Slim Sutra Slimming and Yoga Wellness Centre

Breakthrough Innovation in Cosmetic Dermatology

Dr. Rashmi Shetty

Excellence in Clinical Pharmacology & Medico- Marketing

Dr. Dilip Pawar

Emerging Anti-Aging  & Obesity Management Pharma Company

AVI Pharma Pvt. Ltd

India’s Most Admired Hair Transplant Surgeon 2015

Dr. Manoj Khanna

Company of the year 2015

Wallace Pharmaceuticals Ltd

Imagine India, If the Healthcare Insurance is covered to even half the population, India’s ranking in the World will increase!

Imagine India, If the Healthcare  Insurance  is covered to even half the population,  India’s ranking in the World will increase!

Government Regulation to curb sky-rocketing expenses  of Private Hospitals will be a Big Relief to the Rising Indian Middle Class!

India has double digit medical inflation. On the other hand, health cover is not adequate, and even employers’ health cover is insufficient in many cases, and individuals end up paying from their own pockets many a times. And, even though the premiums for health insurance have remained relatively stagnant, it has been mainly thanks to competition among the insurers. According to the report: Over the last four years, premiums of most insurers have increased only once – in 2014 – over the previous year, reflecting a CAGR of 2.79% (for sum insured of Rs 2,00,000 and Rs 3,00,000) and 3.29% (for sum insured Rs 5,00,000 and Rs 10,00,00).

95% of middle-class Indians do not have enough health insurance

The Big Picture

An increased appreciation of rapidly rising healthcare treatment costs does not seem to have translated into Indian consumers being better prepared. This is either because we, as consumers believe that we are a genetically healthy bunch or are unaware of just how expensive medical procedures have become. Around 95% of middle-class Indians do not have enough health insurance to cover some of the most common procedures and ailments in the country, according to a report by BigDecisions.com, one of India’s leading personal finance advice platforms. Surprisingly, consumers above 45 who are at higher risk of health problems and closer to retirement, are least prepared for emergencies as they are under-insured by an average of 69%.

An increased appreciation of rapidly rising healthcare treatment costs does not seem to have translated into Indian consumers being better prepared. This is either because we, as consumers believe that we are a genetically healthy bunch or are unaware of just how expensive medical procedures have become. It is getting more expensive to treat some of the most commonly occurring diseases in India. Amid an inflationary environment in India for at least a decade, prices four years ago were not exactly low. The fact that they have again risen, by double digits in some cities, is noteworthy.It is clear that there is room for Indian prices to increase further. We believe that current inflationary trends are likely to continue for the foreseeable future. While it is no surprise that typical treatment costs in the US are sometimes more than 10x what they are in India, that they are more than twice as expensive in countries closer to home such as Malaysia and Thailand, means Indians could soon be paying more.95% of our users are not adequately insured, with 62% of 10,000 BigDecisions users having less than 50% of required health cover. Consumers above 45 (with higher needs, typically higher incomes and fewer years to retirement) are a high-risk group – they are the least prepared for health emergencies as they are under-insured by an average of 69%.

We make the case not only for more resources but for a radically new architecture for India’s health-care system. India needs to adopt an integrated national health-care system built around a strong public primary care system with a clearly articulated supportive role for the private and indigenous sectors. This system must address acute as well as chronic health-care needs, offer choice of care that is rational, accessible, and of good quality, support cashless service at point of delivery, and ensure accountability through governance by a robust regulatory framework. In the process, several major challenges will need to be confronted, most notably the very low levels of public expenditure; the poor regulation, rapid commercialization of and corruption in health care; and the fragmentation of governance of health care. Most importantly, assuring universal health coverage will require the explicit acknowledgment, by government and civil society, of health care as a public good on par with education. Only a radical restructuring of the health-care system that promotes health equity and eliminates impoverishment due to out-of-pocket expenditures will assure health for all Indians by 2022.

translating this vision into action. 

  1. India’s healthcare priority should be to dramatically improve preventive and primary care standards. Its facilities should be strengthened with more personnel, increased capacity building, and rigorous monitoring, all complemented with greater demand-side pressures. The primary health center (PHC) and its subcenters should be trained to act as a single-stop for all preventive and primary care services, and a gatekeeper for all referral services. While this is notionally their mandate even today, its compliance remains weak and these institutions have been reduced to being maternal and child health centers. All the existing national programs, including the village public health activities, should be closely integrated into the PHC and brought under the control of its medical officer. These facilities should be provided resources to equip themselves with all the basic infrastructure and equipments and maintain them in a clean and hospitable manner. Wherever the medical officer is not appointed, a senior staff nurse should be entrusted the supervisory responsibility.
  1. The PHC would act as a nodal agency co-ordinating all preventive and primary care activities – maternal and child health interventions, basic OP services, normal deliveries, administration of national programs, and coordination of village public health activities. This functional profile demands the services of a public health manager, more than a trained medical practitioner, much less one trained rigorously for more than five years. A three-year course with a curriculum designed to accordingly may be one way to also overcome the acute shortage of MBBS doctors that leaves a large proportion of PHCs without any doctor.
  1. Given that less than fully qualified (LTFQ) providers, commonly called quacks, are the point of first contact in nearly 80% of cases in rural areas, no meaningful reform is complete without integrating them into the mainstream. Their capacity building should involve continuous trainings and a gradually phased pathway to formality. One approach may be to offer a very basic preventive and primary care-focused course curriculum as a certificate in primary care, to be acquired over a 4-6 month duration of distance learning. The entire coursework can be provided on-line and through mobile phone apps, with the final examinations too conducted online under strict monitoring. Once they acquire the certification, these providers can be empanelled and used for various preventive and primary care services offered by the government in return for a fee.
  1. The secondary care institutions like the 30-100-bed community health centers (CHCs) should be strengthened with all basic facilities and kept very clean. Currently, they are the weakest part of India’s health care system. These hospitals should contain round-the-clock doctors and be equipped to handle basic surgeries including C-section deliveries. Wherever resources are extremely scarce, staff from two CHCs can be temporarily redeployed to run at least one full-fledged CHC. A mobile team of anesthetists can be made available if required.
  1. All tertiary care admissions, except in cases of emergencies, should happen only through the primary care center and preferably the first referral unit in the CHC. While this may be difficult to enforce, a variety of different approaches may have to be adopted to gradually internalize this approach among all the public and private stakeholders.
  1. It may be difficult to put the insurance genie back in the bottle. The next best option is to consolidate all the public insurance schemes offered to different categories of people under one umbrella, with a basic insurance plan and different types of top-ups, including those which provide premium care. Like in the continental Europe, the basic plan should be community-rated, cover a very basic set of high-incidence catastrophic medical conditions and no more, and have the same premium across insurers within a region. Private insurers should also offer this basic plan and at the same terms. They would be allowed to differentiate based on the top-ups and the quality of their services.
  1. The government, jointly with the private insurance agencies, should negotiate the annual price schedules of care providers and diagnostic services on a regional basis. This price schedule would be applicable for all government and private insurance and for any other contracting of services (like with CGHS). It would be a matter of debate as to whether the fee schedule should become the price standard for all categories of consumers as would be the case in a completely regulated market.
  1. The public tertiary care facilities should be strengthened with more facilities, greater cleanliness and responsiveness, and better management. Since such institutions are only a handful in each state, the state governments should take it up as a mission to bring them up to the standards of the best private hospital in the region. Patients under public insurance or being subsidized for their health care should be discouraged from visiting tertiary care facilities for simple secondary care treatments. Apart from providing affordable and accessible care for the poor, strong public tertiary care facilities are essential to keep private providers honest.
  1. In an environment where government hospitals are badly managed and discourage even those who cannot afford private hospitals, allowing insured citizens to choose their hospital is certain to further enfeeble public facilities. In the circumstances, there may be only two options. One, public insurance schemes can mandate that patients go to private facilities only in case the same treatment is not available at the public facility and on referral by the tertiary care facility (or on pre-authorization by the TPA). Two, the personnel delivering the care in the public facility should be incentivized with a share of the payments. It is not clear as to which of the two alternatives may work and a light-touch mix of both may be necessary.
  1. Finally, districts should be allowed to innovate to implement the components of this plan. The Government of India should offer a menu of interventions to improve health care service delivery – electronic medical records of all medical transactions in public facilities, strengthening of the rogi kalyan samitis at the PHC level, initiatives to make public facilities more attractive for patients, integration of the LTFQ care providers, rating of private providers and so on. The district may commit to the implementation of a clearly defined action plan consisting of some of these interventions and corresponding outcomes and enter into a 3-5 year MoU with the state National Health Mission Society. In return, the district should be encouraged with an incremental share of the NHM allocations. This strategy should not be forced upon all districts. In fact, only a handful of self-selected districts in each state should experiment with it, and based on their learnings, the strategy should be gradually expanded to cover others. Apart from closely monitoring and refining the programs, the state and central governments should encourage competition among those districts in the achievement of their action plans.Now, it would be impossible to implement all these components in a one-size-fits-all mode across the country on a mission mode. It is just too complex. For sure, many of these reforms would struggle to pass the test of political acceptability and seriously strain the administrative bandwidth for effective implementation. Greater program flexibility would certainly lead to failures and scams. Dfferent parts of the country, even parts of the state, will progress at different pace in implementation. But given the enormity of the challenge, this may be the only way to initiate a process which could, potentially, over a long time frame, atleast stand a reasonable chance of getting us to the destination.

Not long ago, consumers could access health information about as easily as they could access plutonium. This is changing rapidly in the information age. As a result, consumers—rather than doctors, government, insurers, hospitals, or healthcare companies—will own the Healthcare Century. Any healthcare institution that ignores this trend does so at its peril.Before the information age, consumers were almost entirely beholden to their physicians for information about health and disease. Now, consumers increasingly educate themselves using the Internet to learn about their health, illnesses, and symptoms. Every day, the patient-doctor relationship becomes more of a partnership as patients come up the learning curve.Previously, the system kept you from your test results until a doctor had time to interpret it for you. Now, mobile health innovations not only allow consumers and caregivers to obtain more data about the body, they also making such data obtainable under consumer control rather than under the control of the healthcare system. Such real-time, self-gathered health data may help the informed healthcare consumer keep doctors away.Until recently, patients were asked to participate in clinical trials about which they knew very little. They underwent therapies that they could not independently research. Informed consent was not very truly informed, and patients were expected to trust the system—a concession of power to experts who might harbor biases or misaligned incentives. In the social media age, consumers are taking back some of that power by tapping into online communities and FDA clinical trial sites to gather additional information.Pricing and performance opacity has long been the norm in healthcare. Stories about the variation in what hospitals charge different patients for the same treatment were once merely anecdotal. Consumers now share their medical bills online, and healthcare pricing data is being aggregated to create transparency for consumers. Similarly, consumers share their performance reviews of doctors and hospitals.Consumers are not only empowering themselves through information about health but also by becoming participants in health innovation. Patient groups such as the Cystic Fibrosis Foundation and Food Allergy Research & Education directly fund and develop novel therapies that benefit patients in partnership with industry. The 2010 Patient Protection and Affordable Care Act established The Patient-Centered Outcomes Research Institute, which enables patients to become directly involved in improving healthcare research and outcomes.Information is power, and a tectonic power shift is catalyzing a revolution in healthcare as information becomes demystified and liberated to consumers. The Gutenberg press liberated the printed word and the human mind, spawning an unprecedented era of human progress. As consumers take control of the future of healthcare, an unprecedented era of medical progress will soon be upon us.


How can you Ensure Healthcare Reforms When Statistics say the real pictures. How to Fix Accountability of Doctors is also a major challenge.

  • There is just one doctor per 2000 people in India
  • There is acute shortage of 64 lakh skilled human resource in the sector
  • The physician density of India per 10,000 populations stands poorly at 6.5 against a global average of 14.2.
  • The density of hospital beds per 10,000 populations, which stands at nine against a global average of 30. doctors don’t want to serve rural India. They are very averse about their posting in countryside areas. maximum doctors in urban India are without the MBBS disagrees.
  • Healthcare Insurance almost non-existent. Unlike in the US, ordinary patients in India have no meaningful insurance to cover healthcare expenses. Most have to pay the medical bill on their own, and an increase in defensive medicine may affect these patients economically. But it is also true that in the absence of any insurance oversight, and without any government regulation, hospital expenses are skyrocketing in India
  • There are just 0.64 doctors and 1.44 nurses for 1,000 Indians. The ratio halves for rural India with a large number of health personnel working in urban areas. Although the number of health personnel has increased the demand for medical treatment has also risen with improvement income in recent years
  • A comprehensive study found that defensive medicine may contribute only 1-2% of the cost of US healthcare.
  • Malpractice liability may have a moderate degree of deterrent effect in countries with an effective regulatory system through medical council or board that routinely uses disciplinary action to curb negligence and unethical behaviour by doctors. Unfortunately, medical councils in India have been riddled with incompetence and deep rooted corruption. Disciplinary action against negligent or unethical doctors by medical councils, which comprise only doctors, is almost non-existent in India

 

Inspirational Social Entrepreneur Dr. Huzaifa Khorakiwala to address on CSR in Pharma Industry – A Case Study at the Historic Pharma Leaders 2015 Summit

An inspiring Social Entrepreneur & an astute Business Leader, Dr. Huzaifa Khorakiwala will be delivering a passionate talk on CSR in Pharma Industry – A Case Study

India, historically, has lacked on social givings. We are a country where giving is mainly done for religious purposes. You ask someone to donate to any temple, church, or mosque, they will happily do so. But the same cannot be said about social givings. Many NGOs depend on Corporate . Statistics show in the UK, more than 80% of households give away to charities. In India, it is a mere 1%, feel social experts. Hence, organisations working in the voluntary sector are left with less choice but to depend on corporates.

Dr. Huzaifa Khorakiwala heads the non-profit organization, Wockhardt Foundation which runs several programmes in health, education, water and sanitation across the breadth of the country. He is also Executive Director of Wockhardt Limited and is also part of the promoter family of Wockhardt Group – a leading pharmaceutical and healthcare group. Dr. Huzaifa Khorakiwala is an MBA from the prestigious Yale University in USA. He has won numerous Awards and is associated with many social causes. He has handled many important positions with Wockhardt, India Center Foundation, Grameen Creative Lab. He is also Executive Director of Wockhardt Limited and is also part of the promoter family of Wockhardt Group – a leading pharmaceutical and healthcare group. He is also the Founder of “The World Peacekeepers Movement”, an online movement comprising of more than a million peacekeepers,

forming the world’s 3rd largest army.He is Chairman and Founder of “CSR Advisors”, a consultancy service for CSR. He is also the Chairman of Tohfaa Gifting – a gifting company